- UID
- 152977
- 性别
- 保密
- 积分
- 340
- 威望
-
- 论坛币
-
- 贡献
-
- 钻石
-
- 主题
- 帖子
- 精华
- 积分
- 340
- 最后登录
- 1-1-1970
- 在线时间
- 小时
|
楼主
7361
16
本内容为网友发布信息,仅代表原作者观点,不代表本平台立场。
原文:h t t p ://news.6park.com/index.php?app=news&act=view&nid=37541
一种被定期注射给六个月以下婴儿,用于预防百日咳、破伤风和脊髓灰质炎等常见儿童病的疫苗被迫大规模召回,原因是生产这种疫苗的比利时工厂内发现了细菌。但该疫苗的生产商表示,疫苗本身并未受到污染,因此家长们可以不必担心。
在比利时的制造工厂发现病菌后,大约11.5万剂Infanrix hexa疫苗正在被澳洲供应商葛兰素史克公司(GlaxoSmithKline Australia,GSK)召回。
此次召回主要是爲了保险起见,被召回的产品涉及6个批次,是在2011年8月到2012年1月期间出货的。GSK说,很多疫苗很有可能已经被澳洲的儿童所使用,但该公司强调说,注射被召回批次的疫苗并没有健康风险。
Infanrix hexa通常被定期给予2个月,4个月和6个月大的婴儿,作为全国预防接种计划(National Immunisation Program)的一部分。它被用来防止六种疾病:白喉(diphtheria),破伤风( tetanus),百日咳(pertussis或称whooping cough),乙型肝炎(hepatitis B),脊髓灰质炎(poliomyelitis (或称polio)和B型嗜血杆菌(Haemophilus influenzae type b或称Hib)。
每年有30万名婴儿注射这种疫苗。8岁以下的儿童如果此前不曾接种,也会被注射这种疫苗。
在制造工厂内发现的蜡样芽状杆菌(Bacillus cereus)是一种常见于食物和土壤中的细菌,该细菌对人类具有毒性,可以引发腹泻及呕吐。但被召回批次的疫苗中并未被检出细菌污染。
澳洲药品管理局TGA的一名女发言人表示:“如果你的孩子已经接种了受到影响的批次,他/她既不需要额外的监测,也不需要重新接种疫苗。家长们若对此有任何问题和疑虑,应该向他们的疫苗供应机构或其他专业医疗人士咨询。”
GSK公司的一名发言人说,该公司在11天的时间内迅速采取行动,找回了受影响的疫苗。GSK于9月28日确认疫苗的生产现场存在细菌,随后于10月4日作出了召回决定。他说:“澳洲GSK公司于10月8日星期天获知此事,10月9日星期一便向TGA进行了通报并开始召回产品。”
若有婴儿在接种这一疫苗后出现任何不良反应,请家长立即拨打GSK GSK Medical Information热线1800 033 109及向各州的卫生厅报告。
Press Releases
11 Oct 2012 - Voluntary recall of six batches of Infanrix hexa®
GSK is working with the Therapeutic Goods Administration (TGA) to voluntarily recall for quality reasons 6 batches of Infanrix hexa in Australia. These were dispatched from GSK between August 2011 and January 2012 and are being recalled solely as a precautionary measure.
GSK has multiple quality controls in place for facilities, equipment and products. Testing by GSK has identified that one step of the vaccine manufacturing process was found to have a low level contamination.
No contamination has been found in the vaccine itself and all vaccine batches and ingredients have passed the stringent quality and sterility testing required to be released for use in Australia.
This recall is precautionary. Anyone vaccinated with a dose of Infanrix hexa does not need to take any action. There is no need for revaccination.
“Based on release specifications and safety report monitoring, GSK believes the effectiveness and safety profile of the vaccine remains unchanged. We also believe this issue poses no health risk to patients. This voluntary recall is being taken solely as a precautionary measure,” said Andrew Yeates, GSK Medical Director.
GSK maintains a global database of side effects reported for medicines and vaccines manufactured by the company. A search of this database found no change in reporting pattern since the identified batches have been released. To date no reported adverse events have been directly linked to this issue.
As usual, any adverse events following immunisation should be reported to GSK Medical Information on 1800 033 109. Adverse events should also be reported to State and Territory Health Authorities.
Infanrix hexa (administered at 2, 4 and 6 months of age) is provided as part of the National Immunisation Program and is used to protect against diphtheria, tetanus, whooping cough, hepatitis B, polio and Hib disease.
The batches identified are: A21CB144A, A21CB188D, A21CB188E, A21CB190A, A21CB197A, and A21CB221B. These were dispatched from GSK between August 2011 and January 2012.
-ends-
For further information please contact:
Ken Griffin
Tel: + 61 3 9413 4560
Mobile: +61 477 322 431
[email protected]
Lisa Maguire
Tel: + 61 3 9721 6637
Mobile: +61 449 950 745
[email protected]
|
BBS提醒: 请避免提前支付订金、押金等任何费用,请与对方当面沟通,确认资质并看清条款。谨防上当受骗。
免责声明: 本网站所提供的信息,只供参考之用。本网站不保证信息的准确性、有效性、及时性和完整性。本网站及其雇员一概毋须以任何方式就任何信息传递或传送的失误、不准确或错误,对用户或任何其他人士负任何直接或间接责任。在法律允许的范围内,本网站在此声明,不承担用户或任何人士就使用或未能使用本网站所提供的信息或任何链接所引致的任何直接、间接、附带、从属、特殊、惩罚性或惩戒性的损害赔偿。
|